**Analysis:**

Johnson & Johnson (J&J) reported strong sales and earnings for the second quarter, with a few notable highlights:

1. **Innovative Medicine:** Sales increased by 7.8% worldwide, driven by growth in key brands and recently launched products. Notable products like CARVYKTI, TECVAYLI, and ERLEADA showed strong growth. The company expects continued uptake from these products and is optimistic about the future launch of RYBREVANT plus Lazertinib and TREMFYA in IBD.

2. **MedTech:** Sales increased by 4.4% worldwide, with growth in the U.S. and outside the U.S. The company expects growth to accelerate in the second half of the year, driven by continued expansion of new products and commercial execution across the portfolio.

3. **Guidance:** The company provided updated guidance for 2024, with adjusted operational EPS expected to increase by $0.05 per share, resulting in year-over-year EPS growth of 8.2% at the midpoint. Sales growth is expected to be between 6.1% and 6.6% compared to 2023.

**Short-term implications:**

- The strong Q2 results and guidance suggest that J&J is well-positioned to continue its growth trajectory in 2024.
- The launch of RYBREVANT plus Lazertinib and TREMFYA in IBD could be significant drivers of growth in the coming quarters.
- The company's commitment to innovation and strategic acquisitions, such as Shockwave and Proteologix, indicates a focus on long-term growth.

**Rating:**

Based on the strong results, updated guidance, and the company's focus on innovation and strategic growth, the short-term impact on the stock price is expected to be **positive**.